Matt Ridley

Could a vaccine for cancer be within reach?

issue 25 June 2022

It’s probably now the longest running conflict since the Hundred Years’ War: Richard Nixon declared the ‘war on cancer’ 51 years ago. The enemy is still in the field, killing more people than ever as other causes of mortality shrink. But cancer is at last giving ground.

Fresh from its triumph in the race to make a vaccine for Covid-19, the German biotech company BioNTech has announced promising results using a similar vaccine against pancreatic cancer. Of 16 people given the vaccine shortly after they had their tumour surgically removed, eight were cancer-free 18 months later. That may not sound like much and these are small numbers, but they are being greeted with enthusiasm. Pancreatic cancer is usually lethal within a year because it shows few symptoms till it has spread to the rest of the body, and this was just a phase-1 trial, intended to test the safety rather than the efficacy of the treatment.

Written by
Matt Ridley
Matt Ridley is the author of How Innovation Works: And Why It Flourishes in Freedom (2020), and co-author of Viral: The Search for the Origin of Covid-19 (2021)

Topics in this article

Comments

Join the debate for just $5 for 3 months

Be part of the conversation with other Spectator readers by getting your first three months for $5.

Already a subscriber? Log in